John P Burke1, Glen A Doherty, P Ronan O'Connell. 1. Department of Colorectal Surgery, St Vincent's University Hospital and School of Medicine and Medical Sciences, University College Dublin, Dublin 4, Ireland. drjohnpburke@yahoo.ie
Abstract
BACKGROUND AND AIMS: Post-operative Crohn's disease (CD) recurrence is common after intestinal resection. The European Crohn's and Colitis Organization has issued guidelines regarding the optimal post-operative management of patients who have undergone intestinal resection for CD. The current study aims to assess the current adjuvant therapy practices of colorectal surgeons and gastroenterologists. METHODS: An electronic-based survey was sent to members of the Association of Coloproctology of Great Britain and Ireland and the Irish Society of Gastroenterology. RESULTS: One hundred twenty-five surgeons and gastroenterologists responded. Gastroenterologists more frequently assessed for pre-clinical recurrence with serum inflammatory markers (97 vs. 51%, P < 0.001), faecal calprotectin (30 vs. 10%, P = 0.008) and ileocolonoscopy (67 vs. 23%, P < 0.001), while surgeons more frequently performed a CT scan (23 vs. 6%, P = 0.037). The majority of respondents estimated the 1-year endoscopic recurrence to be 10-25%, and 36% of respondents offered prophylaxis to all post-operative patients. Budesonide (8 vs. 4%, P = 0.006) and azathioprine/mercaptopurine (60 vs. 33%, P < 0.001) were more often prescribed for high-risk patients, while imidazole antibiotics (11 vs. 5%, P < 0.001) and 5-ASA derivatives were more often prescribed for low-risk patients (51 vs. 14%, P < 0.001). CONCLUSION: Currently, surgeons and gastroenterologists involved in the peri-operative care of patients with CD underestimate the risk of recurrence following intestinal resection and under-utilize ileocolonoscopy to tailor adjuvant therapy.
BACKGROUND AND AIMS: Post-operative Crohn's disease (CD) recurrence is common after intestinal resection. The European Crohn's and Colitis Organization has issued guidelines regarding the optimal post-operative management of patients who have undergone intestinal resection for CD. The current study aims to assess the current adjuvant therapy practices of colorectal surgeons and gastroenterologists. METHODS: An electronic-based survey was sent to members of the Association of Coloproctology of Great Britain and Ireland and the Irish Society of Gastroenterology. RESULTS: One hundred twenty-five surgeons and gastroenterologists responded. Gastroenterologists more frequently assessed for pre-clinical recurrence with serum inflammatory markers (97 vs. 51%, P < 0.001), faecal calprotectin (30 vs. 10%, P = 0.008) and ileocolonoscopy (67 vs. 23%, P < 0.001), while surgeons more frequently performed a CT scan (23 vs. 6%, P = 0.037). The majority of respondents estimated the 1-year endoscopic recurrence to be 10-25%, and 36% of respondents offered prophylaxis to all post-operative patients. Budesonide (8 vs. 4%, P = 0.006) and azathioprine/mercaptopurine (60 vs. 33%, P < 0.001) were more often prescribed for high-risk patients, while imidazole antibiotics (11 vs. 5%, P < 0.001) and 5-ASA derivatives were more often prescribed for low-risk patients (51 vs. 14%, P < 0.001). CONCLUSION: Currently, surgeons and gastroenterologists involved in the peri-operative care of patients with CD underestimate the risk of recurrence following intestinal resection and under-utilize ileocolonoscopy to tailor adjuvant therapy.
Authors: Miguel Regueiro; Sandra El-Hachem; Kevin E Kip; Wolfgang Schraut; Leonard Baidoo; Andrew Watson; Jason Swoger; Marc Schwartz; Arthur Barrie; Marilyn Pesci; David Binion Journal: Dig Dis Sci Date: 2011-06-17 Impact factor: 3.199
Authors: T D Walters; A H Steinhart; C N Bernstein; W Tremaine; M McKenzie; B G Wolff; R S McLeod Journal: Inflamm Bowel Dis Date: 2010-11-15 Impact factor: 5.325
Authors: In Young Choi; Sang Hyoung Park; Seong Ho Park; Chang Sik Yu; Yong Sik Yoon; Jong Lyul Lee; Byong Duk Ye; Ah Young Kim; Suk-Kyun Yang Journal: Korean J Radiol Date: 2017-09-21 Impact factor: 3.500